Paper Details

  1. Home
  2. Paper Details

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.

Author: AbraoMauricio S, ArcherDavid F, CarrBruce R, ChwaliszKristof, DiamondMichael P, DmowskiW Paul, DuanW Rachel, GallagherJ Chris, GiudiceLinda C, JainRita I, JohnsonNeil P, KotarskiJan, LesseyBruce A, LeylandNicholas, NgJuki, RowanJean P, SchwefelBrittany, SimonJames A, SurreyEric, TaylorHugh S, ThomasJames W, WattsNelson B

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist, was effective in improving dysmenorrhea and nonmenstrual pelvic pain in women with endometriosis-associated pain.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies. METHODS: We performed two similar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1700089

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Endometriosis: The Potential of Elagolix

Endometriosis, like a stubborn desert cactus, can bring persistent pain and discomfort. This study explores the potential of elagolix, a new oral GnRH antagonist, for treating endometriosis-associated pain. The authors conducted two large-scale phase 3 trials to evaluate the effectiveness of elagolix in reducing pain and improving quality of life for women with endometriosis.

The study found that elagolix, at both higher and lower doses, was effective in reducing dysmenorrhea (menstrual pain) and nonmenstrual pelvic pain in women with endometriosis. The authors observed significant improvements in pain scores and a decrease in the use of rescue analgesics. However, the study also noted that elagolix was associated with some hypoestrogenic side effects, such as hot flushes and changes in lipid levels.

A New Path to Relief in the Desert of Endometriosis

The study suggests that elagolix could be a valuable new treatment option for women with endometriosis. The findings offer hope for individuals seeking alternative treatments and emphasize the importance of weighing the potential benefits against the risks of side effects.

Navigating the Desert of Endometriosis: Informed Choices

This study underscores the importance of open communication with healthcare providers when discussing treatment options for endometriosis. Patients can discuss their concerns, preferences, and potential side effects to make informed decisions about their care.

Dr.Camel's Conclusion

This study presents elagolix as a promising new treatment option for endometriosis-associated pain. The findings offer a glimmer of hope for individuals seeking relief from this often-debilitating condition. However, it's important to discuss the potential benefits and risks of elagolix with your healthcare provider to determine if it's the right treatment for you.

Date :
  1. Date Completed 2017-07-11
  2. Date Revised 2018-03-16
Further Info :

Pubmed ID

28525302

DOI: Digital Object Identifier

10.1056/NEJMoa1700089

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.